BiotechTube
LifeSpan Biosciences

LifeSpan Biosciences

Seattle, United States· Est.
lsbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $10M

Overview

LifeSpan Biosciences (LSBio) is a long-established, privately held reagent supplier specializing in validated antibodies and assay kits for life science research. The company has built a strong reputation, particularly in the immunohistochemistry (IHC) space, with its proprietary IHC-plus™ and PathPlus™ antibody validation platforms. Its extensive catalog of nearly 500,000 antibodies and associated products supports research in key areas like oncology, virology, and neurodegenerative diseases. Operating as a revenue-generating business-to-business (B2B) model, LSBio competes in the global research tools and diagnostics market by emphasizing rigorous validation and a broad product portfolio.

OncologyInfectious DiseaseNeurodegenerative Disease

Technology Platform

Proprietary antibody validation platforms (IHC-plus™, PathPlus™) for highly specific and sensitive immunohistochemistry (IHC) on FFPE tissue. Expertise in developing diverse ELISA kit formats (Traditional, Cell-Based, DNA-Binding, Chemiluminescent CLIA) and producing recombinant/native proteins.

Funding History

2
Total raised:$10M
Series A$8M
Seed$2M

Opportunities

Growing demand for validated reagents due to the reproducibility crisis in research provides a strong tailwind.
Expansion in high-growth areas like immuno-oncology biomarker research and infectious disease (e.g., pandemic preparedness) offers clear paths for catalog growth and increased market share.

Risk Factors

Faces intense competition from large, diversified life science tools companies and low-cost producers.
Heavy reliance on IHC technology could be a vulnerability if research trends shift significantly.
Revenue is tied to cyclical research funding from academic and biopharma sectors.

Competitive Landscape

LSBio competes in the crowded global life science reagents market against giants like Thermo Fisher Scientific, Abcam, and Merck Millipore, as well as specialized antibody companies. Its differentiation is its deep focus on and validation for IHC, a key technique in pathology. It competes directly with companies like Cell Signaling Technology and Agilent/Spring Bioscience in the premium validated antibody space.

More companies in Antibody-Drug Conjugates →More companies in United States →